

Association of Polymorphisms in One-Carbon Metabolism Genes and Postmenopausal Breast Cancer Incidence

Victoria L. Stevens, Marjorie L. McCullough, Alexandre L. Pavluck, Jeffrey T. Talbot, Heather S. Feigelson, Michael J. Thun, and Eugenia E. Calle

Department of Epidemiology and Surveillance Research, American Cancer Society, Atlanta, Georgia

Abstract

The interconversion of folates by the one-carbon metabolism pathway is essential for the synthesis of precursors used in DNA synthesis, repair, and methylation. Perturbations in this pathway can disrupt these processes and are hypothesized to facilitate carcinogenesis. We investigated associations of 25 candidate polymorphisms in nine one-carbon metabolism genes with risk of postmenopausal breast cancer using 502 cases and 505 controls from the Cancer Prevention II Nutrition Cohort. Four single nucleotide polymorphisms (SNP) in three different genes were significantly associated with breast cancer. The nonsynonymous R134K SNP in *methylenetetrahydrofolate dehydrogenase/methenyltetrahydrofolate cyclohydrolase/formyltetrahydrofolate synthase* [*MTHFD1*; odds ratio (OR), 1.40; 95% confidence interval (95% CI), 1.06-1.85 for CT + TT] and an intronic SNP in *formyltetrahydrofolate dehydrogenase* (*FTHFD*; OR, 2.23; 95% CI, 1.09-4.54 for CC) were associated with a significant

increase in risk. Significantly decreased risk was associated with an intronic SNP in *FTHFD* (OR, 0.75; 95% CI, 0.58-0.98 for CT + CC) and the A360A SNP in *cystathionine β -synthase* (*CBS*; OR, 0.63; 95% CI, 0.41-0.96 for TT). The presence of at least one variant from both the *methylenetetrahydrofolate reductase* (*MTHFR*) C677T and A1298C SNPs was also associated with increased risk (OR, 2.16; 95% CI, 1.34-3.48 for 677 CT + TT/1,298 AC + CC). Investigations into interactions of the associated SNPs with each other and with dietary factors yielded inconclusive results. Our findings indicate that genetic variation in multiple one-carbon metabolism genes may influence risk of postmenopausal breast cancer and may involve changes in methyl donor synthesis. However, larger studies are needed to further examine gene/gene and gene/diet interactions in this pathway. (Cancer Epidemiol Biomarkers Prev 2007; 16(6):1140-7)

Introduction

Breast cancer is the most common incident cancer and second most common fatal cancer among women in the United States. The American Cancer Society estimates that 178,480 new cases of invasive breast cancer and 40,460 deaths from breast cancer will occur in 2007 (1). Many established risk factors for breast cancer, which include age, family history, and other factors such as parity and age at menarche that influence estrogen exposure, are not readily modifiable. Therefore, there is considerable interest in identification of risk factors that can be modified to reduce risk of breast cancer. Among those for which evidence of protective role in this cancer has been accumulating is the B vitamin folate.

As an essential nutrient, folate is needed for DNA synthesis, repair, and methylation. A complex set of reactions (shown in Fig. 1), which cumulatively are known as one-carbon metabolism, convert folate into the forms needed for the various reactions by changing its oxidation status and adding or removing one-carbon groups. Other nutrients, including vitamin B₆, vitamin B₁₂, and methionine, are also required for this pathway. Because all of these reactions are interconnected, an insufficient supply of one substrate can alter the levels of numerous other metabolites generated by the pathway. Folate deficiency can compromise nucleotide synthesis, leading to an imbalance in the levels of dUMP and dTMP and the subsequent misincorporation of uracil into DNA in place of thymidine (2). This misincorporated uracil is

poorly repaired and can lead to mutations and chromosomal breaks (3). Perturbations in folate metabolism can also compromise the synthesis of S-adenosylmethionine, the donor of the methyl group for DNA methylation. The DNA hypomethylation that results (4) from limiting availability of S-adenosylmethionine can potentially alter gene expression and decrease chromosomal stability. All of these mechanisms contribute to genetic instability and may facilitate carcinogenesis, thus leading to the hypothesis that imbalances in folate metabolism can influence cancer risk.

The findings of numerous studies that investigated the association of folate with breast cancer incidence were reviewed and subjected to meta-analyses (5). The summary odds ratio (OR) from 13 case-control studies [OR, 0.91; 95% confidence intervals (95% CI), 0.87-0.96] suggested that increased folate was associated with decreased risk of breast cancer (5). No evidence for any association with breast cancer was found from nine cohort studies (OR, 0.99; 95% CI, 0.98-1.01). However, five of the cohort studies found that higher folate intake attenuated the increased risk associated with alcohol consumption (6-10), which inhibits folate absorption (11). Numerous factors could contribute to variability in the findings of these studies, including differences in the study populations, variation in the detail of the dietary assessment and the ranges of folate intakes, unaccounted for effects of folate fortification, inconsistent consideration of the disparate bioavailability of various folates, or differential sensitivities to the consequences of low folate intakes because of genetic variation in the one-carbon metabolism enzymes.

Several studies have addressed this latter possibility, focusing primarily on two common nonsynonymous single nucleotide polymorphisms (SNP) in the *methylenetetrahydrofolate reductase* (*MTHFR*) gene: C677T and A1298C. Neither of these SNPs were found to be associated with breast cancer risk by a meta-analysis of 17 studies (5) or a more recent case-control study not included in the meta-analysis (12). Other

Received 12/11/06; revised 2/22/07; accepted 3/19/07.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Requests for reprints: Victoria L. Stevens, Department of Epidemiology and Surveillance Research, American Cancer Society, 1599 Clifton Road, Northeast, Atlanta, GA 30329. Phone: 404-329-5197; Fax: 404-327-6450. E-mail: Victoria.Stevens@cancer.org

Copyright © 2007 American Association for Cancer Research.

doi:10.1158/1055-9965.EPI-06-1037

contained 400 µg folic acid. Nutrient values were energy adjusted using the residuals method (22).

The FFQ was validated among 441 Nutrition Cohort participants who completed four 24-h dietary recall interviews and a repeat FFQ. The validity coefficient in women for dietary folate between the FFQ and dietary recall interviews was 0.43, and the reproducibility between the baseline FFQ and repeat FFQ was 0.66 (23).

Statistical Analysis. The statistical significance of the difference in allele distribution of each polymorphism between cases and controls was calculated using the χ^2 test with 1 degree of freedom. OR and 95% CI for the association between the folate gene polymorphisms and breast cancer incidence were determined using unconditional logistic regression. All models were adjusted for age (in single year categories), race (White, other), date of blood draw (in single year categories), history of breast cyst (yes, no, missing), hormone replacement therapy use (none, former estrogen replacement therapy, current estrogen replacement therapy, former combined hormone replacement therapy, current combined hormone replacement therapy, unknown), and combined age at first birth and parity (nulliparous, age 15 to <25 and 1 or 2 births, age \geq 25 and 1 or 2 births, age 15 to <25 and 3-9 births, age \geq 25 and 3-9 births, unknown).

Effect modification of the association between the SNPs and breast cancer was examined using the likelihood ratio test for dietary and total folate, vitamin B₁₂, vitamin B₆, methionine, fruit and vegetable intake (each using cutoffs below versus at or above median), multivitamin use (non-use versus any use), and alcohol intake (none versus any). We also examined polymorphisms according to "high-risk" diet group (below median dietary folate and methionine intake and consumers of any alcohol) versus "low-risk" diet group (above median dietary folate and methionine intake and a nondrinker).

Gene/gene interactions between pairs of SNPs with significant main effects were evaluated using the likelihood ratio test. The association of combinations of variants with breast cancer incidence was evaluated by classifying each subject by the total number of risk or protective alleles present. "Risk" alleles were defined as those alleles that were independently associated with an increased risk (*MTHFR* C677T T, *MTHFR* A1298C C, *MTHFD1* rs1950902 T, and *FTHFD* rs2276731 C), whereas protective alleles were those associated with a statistically significant decreased risk of breast cancer (*CBS* rs1801181 T and *FTHFD* rs2002287 C). OR and 95% CI were then calculated using unconditional logistic regression. The reference groups for these analyses were subjects with no protective alleles and, because very few women had no alleles associated with increased risk, a combination of women with 0 or 1 risk allele.

Results

The 25 polymorphisms genotyped in the nine folate pathway genes, their location in the gene, the associated amino acid change they caused, and the frequency of the minor allele in cases and controls are listed in Table 1. No significant difference in allele frequencies were found for the majority of the variants. However, as indicated by the unadjusted *P* values shown in this table, four SNPs differed significantly in prevalence of the minor allele between cases and controls. The multivariate-adjusted associations of these SNPs and the two frequently studied SNPs in the *MTHFR* gene with breast cancer incidence among all cases and invasive cases are shown in Table 2. The T allele of the *MTHFD1* R134K SNP and the CC genotype of the *FTHFD* rs2276731 (T/C) SNP were associated with significantly higher breast cancer risk (OR, 1.40; 95% CI, 1.06-1.85 for *MTHFD1* R134K CT + TT and OR, 2.23; 95% CI, 1.09-4.54 for *FTHFD* CC). The C allele of the *FTHFD* rs2002287

(T/C) SNP and the homozygous TT genotype of the *CBS* A360 SNP were associated with significantly lower breast cancer risk (OR, 0.75; 95% CI, 0.58-0.98 for *FTHFD* rs2002287 CT + CC and OR, 0.63; 95% CI, 0.41-0.96 for *CBS* A360A TT). Findings were similar in analyses restricted to invasive breast cancer.

Both the *MTHFR* C677T and A1298C SNPs alter the amino acid sequence of this protein and affect its enzymatic activity, and many studies have investigated the association of these polymorphisms with breast cancer risk (5, 12, 24). We found that the presence of the minor alleles for the C677T and A1298C SNPs in the *MTHFR* gene were associated with increased risk that was not statistically significant (Table 2). The associations of combinations of these polymorphisms with breast cancer risk are shown in Table 3. The presence of at least one variant allele of both SNPs (CT + TT/AC + CC) was associated with a higher risk of breast cancer (OR, 2.16; 95% CI, 1.34-3.48) than those with one or two copies of the variant allele of only one SNP. A similar association was observed when the analysis was limited to women with invasive breast cancer (data not shown).

We were unable to assess interactions among the six SNPs listed in Table 2 considering each polymorphism separately because many of the subgroups contained few cases and controls. As an alternative approach, we grouped alleles associated with increased (risk alleles) or decreased (protective alleles) of breast cancer to determine if having more of each type of allele strengthened the association (Table 4). The "protective" alleles were *FTHFD* rs2002287 (T/C) C and *CBS* A360A T, and women could have zero to four of these alleles. An increasing number of "protective" alleles was inversely associated with breast cancer risk (OR, 0.63; 95% CI, 0.24-1.66 for four alleles; $P_{\text{trend}} = 0.008$). For risk alleles, the *MTHFR* rs1801133 (C677T) T, *MTHFR* rs1801131 (A1298C) C, *MTHFD1* rs1950902 (R134K) T, and *FTHFD* rs2276731 (T/C) C were considered. Although it was theoretically possible to have up to 8 copies of these alleles, no women had more than five risk alleles. Women with zero and one risk allele were combined to increase the stability of the reference group. An increased number of risk alleles was found to be associated with greater risk of breast cancer than any individual SNP alone (OR, 2.13; 95% CI, 0.57-7.96 for five alleles; $P_{\text{trend}} = 0.0001$). Additional adjustment for the number of alleles of the opposite type had little effect on these associations.

A number of substrates and cofactors involved in one-carbon metabolism, including folate, vitamin B₁₂, vitamin B₆, and methionine, are obtained from the diet. Therefore, the influence of different levels of intake of these nutrients as well as other dietary factors that can affect their availability (i.e., alcohol) on the associations of the various SNPs with breast cancer risk was investigated. The *MTHFR* C677T/folate interactions and three other gene/diet interactions found to be statistically significant out of the 48 examined are shown in Table 5. Neither dietary nor total folate modified the association of the *MTHFR* C677T SNP with postmenopausal breast cancer. However, significant interactions were found for the *MTHFR* A1298C SNP and both total folate and alcohol. The presence of the variant allele was associated with higher risk only among women with total folate intake at or above the median (OR, 1.53; 95% CI, 1.12-2.09) and those who consumed alcohol (OR, 1.70; 95% CI, 1.15-2.52). The other significant interaction found was between the *FTHFD* rs2002287 (T/C) SNP and methionine. The protective effect of this SNP was greater in women who consumed the median level or higher of this amino acid (OR, 0.62; 95% CI, 0.45-0.85). No statistically significant interactions were found for the any of the other SNPs.

Evaluation of effect modification by the collective influence of dietary folate, methionine, and alcohol intake using median intake cut points revealed no clear relationships, possibly due to the limited sample sizes in the low- and high-risk groups (data not shown).

Discussion

In this nested case-control study of nine one-carbon metabolism genes, which is the most comprehensive investigation of this pathway in breast cancer to date, we found significant associations for four SNPs in three genes. Using $P < 0.05$ to define statistical significance, we expected to find at least one significant association among the 25 polymorphisms genotyped simply due to chance. The P values for the four significant (at $P < 0.05$) SNPs ranged from 0.022 to 0.048, and correction of these values for multiple comparisons using any method would result in all of these associations being judged as not statistically significant. However, it seems unlikely that all four of these associations are false positives. Therefore, rather than presenting our results corrected for multiple comparisons, we have chosen to interpret our results as indicating that some, but not all, of the four SNPs with $P < 0.05$ reflect true associations with breast cancer. However, we are unable to conclude which of the four are true positives using this approach.

The R134K SNP in the *MTHFD1* gene was associated with increased risk of breast cancer. *MTHFD1* is a trifunctional cytosolic enzyme whose three activities can cooperate to generate 10-formyltetrahydrofolate, which donates its formyl group in two different steps in purine biosynthesis. The methylenetetrahydrofolate dehydrogenase and methenyltetrahydrofolate cyclohydrolase activities, which reside together in one domain of the protein, catalyze the oxidation of 5,10-methylenetetrahydrofolate to 5,10-methenyltetrahydrofolate, which is then converted to 10-formyltetrahydrofolate. The

synthetase activity resides in a separate protein domain and catalyzes the synthesis of 10-formyltetrahydrofolate from formate and tetrahydrofolate. The R134K SNP changes an arginine to a lysine in the dehydrogenase/cyclohydrolase domain of *MTHFD1* and may affect these activities. However, no studies have investigated the functional consequences of this SNP, and the only study to investigate the R134K SNP in relation to disease did not find an association with altered risk of neural tube defects (25). Altered dehydrogenase/cyclohydrolase activity could either affect the forward reaction and alter supply of formyltetrahydrofolate for purine synthesis or perturb the reverse reaction and influence the availability of 5,10-methylenetetrahydrofolate, which either could be used by *MTHFR* and feed into homocysteine remethylation or by *TYMS* for dTMP synthesis. Substrate binding and kinetic studies have suggested that the forward and reverse reactions of the *MTHFD* dehydrogenase/cyclohydrolase activities are in equilibrium (26, 27). Therefore, whether the availability of 5,10-methylenetetrahydrofolate or 10-formyltetrahydrofolate is affected would depend on the tissue levels of these folates and how the dehydrogenase and cyclohydrolase activities are perturbed by the polymorphism.

Two SNPs in the *FTHFD* gene (also known as *ALDH1L1*) were significantly associated with altered risk of breast cancer. *FTHFD* catalyzes the conversion of 10-formyltetrahydrofolate to tetrahydrofolate and CO_2 . Despite the fact that 10-formyltetrahydrofolate, the substrate for *FTHFD*, is required for purine biosynthesis, altered expression of this enzyme does not influence nucleotide metabolism (28). Rather, changes in *FTHFD* expression have been found to regulate the levels of

Table 1. Characteristics and genotype frequencies of the folate gene polymorphisms analyzed in this study among cases and controls

| Gene/SNP* | Location | AA change | Minor allele | Minor allele frequency | | P^{\dagger} |
|------------------------|-----------|-----------|--------------|------------------------|----------|---------------|
| | | | | Cases | Controls | |
| <i>MTHFR</i> | | | | | | |
| rs1801133 (C677T) | Exon 5 | Val → Ala | T | 35.2 | 32.7 | 0.24 |
| rs1801131 (A1298C) | Exon 8 | Ala → Glu | C | 31.6 | 28.5 | 0.14 |
| rs2066470 (T118C) | Exon 2 | None | T | 10.0 | 7.8 | 0.094 |
| <i>MTR</i> | | | | | | |
| rs1806505 (C/T) | Intron 13 | NA | T | 40.8 | 43.0 | 0.26 |
| rs1805087 (A2756G) | Exon 26 | Asp → Gly | G | 18.1 | 17.9 | 0.91 |
| rs1050993 (G/A) | 3' UTR | NA | A | 38.1 | 35.4 | 0.21 |
| <i>MTRR</i> | | | | | | |
| rs1801394 (A66G) | Exon 2 | Met → Ile | A | 43.3 | 43.6 | 0.90 |
| rs10380 (C1785T) | Exon 14 | Tyr → His | T | 8.7 | 10.1 | 0.29 |
| <i>SHMT1</i> | | | | | | |
| rs643333 (C/A) | 5' UTR | NA | A | 29.1 | 28.9 | 0.90 |
| rs2273028 (C/T) | Intron 7 | NA | T | 31.2 | 32.2 | 0.66 |
| rs1979277 (C1420T) | Exon 12 | Leu → Phe | A | 31.0 | 31.2 | 0.92 |
| <i>MTHFD1</i> | | | | | | |
| rs1076991 (A/G) | 5' UTR | NA | G | 45.8 | 46.5 | 0.76 |
| rs1950902 (R134K) | Exon 6 | Arg → Lys | T | 19.2 | 15.8 | 0.048 |
| rs2236224 (C/T) | Intron 21 | NA | T | 38.4 | 41.0 | 0.24 |
| rs2236225 (R653Q) | Exon 21 | Arg → Gln | T | 43.1 | 45.4 | 0.30 |
| <i>TYMS</i> | | | | | | |
| rs502396 (T/C) | Intro 1 | NA | C | 48.7 | 49.8 | 0.56 |
| rs699517 (C/T) | 3' UTR | NA | T | 33.5 | 33.3 | 0.91 |
| 28-bp Tandem repeat | 5' UTR | NA | 2r | 48.4 | 48.5 | 0.97 |
| <i>DHFR</i> | | | | | | |
| rs1677693 (C/A) | Intron 3 | NA | A | 26.4 | 27.1 | 0.71 |
| rs1643638 (T/C) | Intron 4 | NA | C | 26.2 | 27.5 | 0.52 |
| <i>FTHFD (ALDH1L1)</i> | | | | | | |
| rs2276731 (T/C) | Intron 4 | NA | C | 20.4 | 16.4 | 0.022 |
| rs2002287 (T/C) | Intron 13 | NA | C | 34.2 | 38.8 | 0.034 |
| rs1127717 (A2380C) | Exon 21 | Asp → Gly | G | 18.9 | 19.6 | 0.70 |
| <i>CBS</i> | | | | | | |
| rs234706 (Y233Y) | Exon 8 | None | A | 34.7 | 31.4 | 0.12 |
| rs1801181 (A360A) | Exon 12 | None | T | 32.4 | 36.9 | 0.040 |

Abbreviations: NA, not applicable; UTR, untranslated region.

*The designation by which the SNP is commonly referred to in the literature, when one exists, is shown in parenthesis.

$^{\dagger}P$ for the difference in minor allele frequencies was determined using the χ^2 test with 1 degree of freedom.

Table 2. Association of SNPs in folate pathway genes with incidence of breast cancer in all cases and invasive cases

| Gene/SNP | All cases | | Invasive cases* | |
|--------------------|-------------------|--------------------------|-------------------|--------------------------|
| | No. cases/control | OR [†] (95% CI) | No. cases/control | OR [†] (95% CI) |
| <i>MTHFD1</i> | | | | |
| rs1950902 (R134K) | | | | |
| CC | 316/353 | 1.00 | 241/353 | 1.00 |
| CT | 163/124 | 1.49 (1.12-1.99) | 120/124 | 1.42 (1.04-1.93) |
| TT | 13/16 | 0.77 (0.36-1.68) | 11/16 | 0.88 (0.39-1.97) |
| CT + TT | 176/140 | 1.40 (1.06-1.85) | 131/140 | 1.35 (1.00-1.82) |
| <i>FTHFD</i> | | | | |
| rs2276731 (T/C) | | | | |
| TT | 317/344 | 1.00 | 250/344 | 1.00 |
| CT | 157/136 | 1.23 (0.92-1.63) | 109/136 | 1.10 (0.81-1.50) |
| CC | 23/13 | 2.23 (1.09-4.54) | 18/13 | 2.25 (1.06-4.76) |
| rs2002287 (T/C) | | | | |
| TT | 220/188 | 1.00 | 172/188 | 1.00 |
| CT | 209/229 | 0.76 (0.57-1.00) | 156/229 | 0.72 (0.54-0.97) |
| CC | 64/77 | 0.75 (0.50-1.11) | 45/77 | 0.67 (0.43-1.03) |
| CT + CC | 273/306 | 0.75 (0.58-0.98) | 201/306 | 0.71 (0.54-0.94) |
| <i>CBS</i> | | | | |
| rs1801181 (A360A) | | | | |
| CC | 216/194 | 1.00 | 168/194 | 1.00 |
| CT | 218/214 | 0.92 (0.70-1.22) | 161/214 | 0.87 (0.65-1.18) |
| TT | 47/69 | 0.63 (0.41-0.96) | 33/69 | 0.56 (0.35-0.91) |
| <i>MTHFR</i> | | | | |
| rs1801133 (C677T) | | | | |
| CC | 208/236 | 1.00 | 160/236 | 1.00 |
| CT | 224/193 | 1.34 (1.02-1.77) | 167/193 | 1.27 (0.94-1.72) |
| TT | 62/65 | 1.09 (0.72-1.63) | 47/65 | 1.06 (0.68-1.64) |
| CT + TT | 286/258 | 1.28 (0.98-1.66) | 214/258 | 1.22 (0.92-1.61) |
| rs1801131 (A1298C) | | | | |
| AA | 224/252 | 1.00 | 167/252 | 1.00 |
| AC | 228/201 | 1.28 (0.97-1.67) | 173/201 | 1.31 (0.97-1.75) |
| CC | 42/40 | 1.09 (0.67-1.78) | 35/40 | 1.25 (0.75-2.10) |
| AC + CC | 270/241 | 1.25 (0.96-1.62) | 208/241 | 1.30 (0.98-1.72) |

*Invasive cases include all but *in situ* breast cancers.

†ORs were determined using unconditional logistic regression adjusting for age, race, date of blood draw, history of breast cyst, hormone replacement therapy, and parity.

5-methyltetrahydrofolate and the subsequent remethylation of homocysteine to methionine (28). One *FTHFD* SNP [rs2276731 (T/C)] was associated with increased risk (OR, 2.23; 95% CI, 1.09-4.54 for CC versus TT), whereas the other [rs2002287 (T/C)] was associated with decreased risk (OR, 0.75; 95% CI, 0.58-0.98 for CT + CC versus TT). Neither of these SNPs is expected to alter *FTHFD* activity directly because they are both in introns. Therefore, it is expected that they are in linkage disequilibrium with functional polymorphisms. These two SNPs are in linkage disequilibrium with each other ($D' = 1.0$, $r^2 = 0.082$) and with three nonsynonymous SNPs: rs4646750 (V812I), rs2276724 (G481S), and rs2886059 (F330V). Any of these SNPs may be responsible for the associations found here. The *FTHFD* protein has three separate domains responsible for different parts of the enzymatic reaction and its regulation (29). Therefore, our finding of two different SNPs in this gene being associated with breast cancer risk in disparate ways is not unreasonable because they could influence different properties

Table 3. Association of genotype combinations of the *MTHFR* C677T and A1298C SNPs with breast cancer

| Genotypes | | All cases | |
|-----------|---------|-------------------|------------------|
| C677T | A1298C | No. cases/control | OR* (95% CI) |
| CC | AA | 49/76 | 1.00 (reference) |
| CC | AC + CC | 155/157 | 1.53 (0.99-2.38) |
| CT + TT | AA | 172/174 | 1.56 (1.02-2.40) |
| CT + TT | AC + CC | 111/82 | 2.16 (1.34-3.48) |

*ORs were calculated using unconditional logistic regression adjusting for age, race, date of blood draw, history of breast cyst, hormone replacement therapy, and parity.

of this enzyme. There have been no previous studies of the association of this gene with any cancer.

The A360A SNP in the *CBS* gene was found to be associated with a reduced risk of breast cancer. *CBS* catalyzes the vitamin B₆-dependent trans-sulfuration reaction between serine and homocysteine that results in the formation of cystathionine.

Table 4. Combined effect of genotypes from protective or risk alleles on the risk of breast cancer in all cases

| Allele type/number | Cases | Controls | OR* (95% CI) | OR [†] (95% CI) |
|-------------------------|-------|----------|-----------------------------|-----------------------------|
| Protective [‡] | | | | |
| 0 | 99 | 77 | 1.00 (reference) | 1.00 (reference) |
| 1 | 187 | 164 | 0.87 (0.60-1.27) | 0.89 (0.61-1.30) |
| 2 | 130 | 147 | 0.67 (0.46-1.00) | 0.70 (0.47-1.04) |
| 3 | 50 | 70 | 0.58 (0.36-0.94) | 0.64 (0.39-1.05) |
| 4 | 8 | 11 | 0.63 (0.24-1.66) | 0.70 (0.26-1.89) |
| | | | $P_{\text{trend}} = 0.008$ | $P_{\text{trend}} = 0.029$ |
| Risk [§] | | | | |
| 0 + 1 | 132 | 183 | 1.00 (reference) | 1.00 (reference) |
| 2 | 178 | 172 | 1.49 (1.08-2.04) | 1.44 (1.05-1.98) |
| 3 | 129 | 94 | 1.89 (1.31-2.71) | 1.83 (1.27-2.64) |
| 4 | 33 | 24 | 1.93 (1.07-3.48) | 1.75 (0.96-3.17) |
| 5 | 6 | 4 | 2.13 (0.57-7.96) | 1.95 (0.52-7.30) |
| | | | $P_{\text{trend}} = 0.0001$ | $P_{\text{trend}} = 0.0005$ |

*ORs were adjusted for age, race, date of blood draw, history of breast cyst, hormone replacement therapy, and parity.

†ORs were adjusted for age, race, date of blood draw, history of breast cyst, hormone replacement therapy, parity, and the number of alleles of the opposite type (protective or risk).

‡Protective alleles: *CBS* rs1801181 (A360A) T and *FTHFD* rs2002287 (T/C) C.

§Risk alleles: *MTHFR* rs1801133 (C677T) T, *MTHFR* rs1801131 (A1298C) C, *MTHFD1* rs1950902 (R134K) T, and *FTHFD* rs2276731 (T/C) C.

Table 5. Influence of dietary factors on the association of the *MTHFR* C677C, A1298C and *FTHFD* rs2002287 (T/C) SNPs with breast cancer

| Genotype | Dietary folate | | | |
|---|-------------------|--------------------------|-------------------|--------------------------|
| | <Median | | ≥Median* | |
| | No. cases/control | OR [†] (95% CI) | No. cases/control | OR [†] (95% CI) |
| <i>MTHFR</i> C677T | | | | |
| CC | 100/116 | 1.00 (reference) | 103/108 | 1.00 (reference) |
| CT + TT | 124/121 | 1.17 (0.84-1.63) | 145/129 | 1.23 (0.91-1.88) |
| <i>P</i> _{interaction} = 0.48 | | | | |
| Genotype | Total folate | | | |
| | <Median | | ≥Median* | |
| | No. cases/control | OR [†] (95% CI) | No. cases/control | OR [†] (95% CI) |
| <i>MTHFR</i> C677T | | | | |
| CC | 95/116 | 1.00 (reference) | 108/108 | 1.00 (reference) |
| CT + TT | 110/120 | 1.08 (0.77-1.52) | 159/130 | 1.31 (0.97-1.78) |
| <i>P</i> _{interaction} = 0.067 | | | | |
| <i>MTHFR</i> A1298C | | | | |
| AA | 98/117 | 1.00 (reference) | 113/126 | 1.00 (reference) |
| AC + CC | 106/120 | 1.05 (0.75-1.48) | 155/111 | 1.53 (1.12-2.09) |
| <i>P</i> _{interaction} = 0.03 | | | | |
| Genotype | Alcohol intake | | | |
| | None | | Any | |
| | No. cases/control | OR [†] (95% CI) | No. cases/control | OR [†] (95% CI) |
| <i>MTHFR</i> A1298C | | | | |
| AA | 132/122 | 1.00 (reference) | 92/130 | 1.00 (reference) |
| AC + CC | 154/145 | 0.96 (0.68-1.36) | 116/96 | 1.70 (1.15-2.52) |
| <i>P</i> _{interaction} = 0.03 | | | | |
| Genotype | Methionine intake | | | |
| | <Median | | ≥Median* | |
| | No. cases/control | OR [†] (95% CI) | No. cases/control | OR [†] (95% CI) |
| <i>FTHFD</i> rs2002287 (T/C) | | | | |
| TT | 107/90 | 1.00 (reference) | 104/87 | 1.00 (reference) |
| CT + CC | 141/143 | 0.83 (0.60-1.15) | 119/154 | 0.62 (0.45-0.85) |
| <i>P</i> _{interaction} = 0.035 | | | | |

*Above median groups include any individuals whose values are at the median.

†ORs were calculated using unconditional logistic regression adjusting for age, race, date of blood draw, history of breast cyst, hormone replacement therapy, and parity.

This reaction serves to metabolize excess homocysteine, and mutations in the *CBS* gene are the most common inborn errors of metabolism that result in hyperhomocysteinemia (30). The A360A SNP causes no change in the *CBS* protein and has no apparent functional consequence. However, this SNP has been inconsistently linked to changes in blood levels of homocysteine (31-33) and associated with a significant increase in risk of lung cancer (34). Thus, the A360A SNP has been proposed to be in linkage disequilibrium with another polymorphism, which has not yet been identified, that is actually responsible of changes in *CBS* activity (32, 34). No common nonsynonymous SNPs have been identified in the *CBS* gene; thus, the polymorphism responsible for the association of the A360A SNP may influence the expression of this gene.

No significant association was found for either of the two commonly studied SNPs in the *MTHFR* gene. However, a significant increase in risk was associated with the presence of at least one variant allele from both the C677T and A1298C SNPs. Whether the risk increases with additional copies of the variant alleles of these SNPs cannot be determined because the strong linkage disequilibrium between these polymorphisms ($D' = 0.79-0.95$ in Caucasian populations; ref. 35) limits the occurrence of these genotype combinations. *MTHFR* catalyzes

the irreversible reduction of 5,10-methyltetrahydrofolate to 5-methyltetrahydrofolate, which is the folate used for the remethylation of homocysteine to methionine. The C677T SNP changes an alanine to valine and results in production of a "thermolabile" enzyme with reduced activity (36, 37). This variant allele has been associated with increased levels of serum or plasma homocysteine and numerous diseases, including several cancers (reviewed in ref. 38). The A1298C SNP leads to a substitution of an alanine for a glutamic acid (39) and also reduces *MTHFR* activity (40). Rather than indicate which SNP is more important, our findings suggest that reduced *MTHFR* activity is linked to increased risk of breast cancer. The null main effect found here for the C677T and A1298C polymorphisms independently is consistent with the results of many of the previous studies (5, 12). However, our finding of increased risk for the combined genotypes is different from all but one (41) of the five previous studies in which both *MTHFR* SNPs were investigated. One study found no association (42), whereas three observed a protective effect (14, 43, 44) when variant alleles from both SNPs were present. Why our results are different from the majority of other studies is not readily apparent but could be due to differences in ethnicity (42, 44), menopausal status (14, 42-44),

background dietary status (42, 43) of some or all of the study subjects, or chance. Furthermore, the value of comparison of our results for the *MTHFR* C677T and A1298C genotype combinations to previous findings is limited because only 5 of 18 studies of this gene in breast cancer (24) have evaluated both SNPs.

One of the major challenges for understanding how perturbations in one-carbon metabolism could influence cancer development is determining which of the cellular processes dependent on this pathway is responsible for the altered risk. Most studies have focused on polymorphisms in *MTHFR* and have suggested that changes in the generation of methyl donors for DNA methylation are responsible for the altered risk of cancer development (45). Our findings of increased risk associated with the *MTHFR* C677T/A1298C genotype combinations and reduced risk associated with the *CBS* gene are consistent with the hypothesis that reduced formation of methyl donors increases risk of breast cancer. For the *CBS* A360A SNP, methylation capacity should be increased in individuals with decreased activity of this enzyme because more homocysteine will be available for remethylation to methionine. Whether the associations of the *MTHFD1* and *FTHFD* SNPs with altered risk of breast cancer are consistent with this hypothesis is unclear because the effect of these polymorphisms on enzyme activity and metabolite levels is not known.

We were unable to investigate interactions between the genes found associated with breast cancer directly because of the small numbers for some genotype combinations. However, we found evidence for cumulative effects of either protective or risk alleles using an allele counting approach. Interpretation of these findings can be difficult because the same results used to define protective and risk alleles are used for the allele counting trend analysis. Increasing numbers of protective alleles from the *CBS* A360A and *FTHFD* rs2002287 (T/C) SNPs yielded a significant trend ($P = 0.008$) with an OR of 0.63 (95% CI, 0.24-1.66) for four of these alleles. This association was of a similar magnitude as found for the *CBS* A360A TT genotype alone and could potentially reflect this SNP alone. However, 53% of the women with three protective alleles did not have the *CBS* A360A TT genotype, suggesting that alleles from the *FTHFD* SNP contributed to the decreased risk observed in these women. Similarly, with the risk alleles, the trend found for increasing number of alleles was highly significant ($P = 0.0001$), but the magnitude of the association was similar to that found for the *FTHFD* rs2276731 (T/C) CC genotype and the *MTHFR* C677T CT + TT/A1298C AC + CC genotype combinations. The increased risk associated with four or five risk alleles could represent the influence of these associations alone. However, 49% of the women with four risk alleles and 20% of those with five risk alleles do not have either the *FTHFD* rs2276731 (T/C) CC genotype or *MTHFR* C677T CT + TT/A1298C AC + CC genotype combination. Therefore, the other risk alleles seem to contribute to this increased risk.

We found few significant interactions between the SNPs associated with altered risk of breast cancer and dietary factors expected to influence one-carbon metabolism. Bonferroni correction of the P values of the three interactions shown in Table 5 results in all having $P_{\text{interaction}} = 1$, indicating that these findings are likely to be due to chance. Previous studies that investigated dietary interactions with the *MTHFR* C677T and the A1298C SNPs in breast cancer have yielded no consistent findings (41-44, 46), and our findings provide no clarification as to whether dietary factors can modify the association of variants in one-carbon metabolism genes on breast cancer risk. Although it may be that there are no interactions of the dietary factors with the folate gene SNPs, results from studies of *MTHFR* SNPs in colorectal cancer (reviewed in ref. 45) and the fact that folate intake has been associated with altered risk of breast cancer (47-50) suggest that significant interactions are possible. Our analyses included fairly narrow ranges of intakes

that limited our ability to examine very low or very high levels of a nutrient. Alternatively, multiple dietary factors may be interacting with the genetic variants at the same time. Assessment of an interaction involving multiple dietary factors, such as found by Giovannucci et al. (51) with colorectal cancer, was investigated but proved uninformative because too few women had dietary patterns expected to be either the best or worst for one-carbon metabolism.

This study is the most comprehensive of one-carbon metabolism genes in breast cancer done to date and, for the *FTHFD* gene and many of the SNPs, is the first to investigate their role in any cancer. An additional strength of this study is availability of prospectively collected information on potential dietary interactions.

A primary limitation of the study is the sample size, which limits our ability to detect statistically significant main effects after correction for multiple comparisons and to evaluate gene-gene and gene-environment interactions. An additional key limitation is the use of only two to four candidate polymorphisms per gene, which prohibits us from conclusively evaluating the role of these one-carbon metabolism genes in determining the risk of postmenopausal breast cancer. The lack of information on the functional consequences of many of the nonsynonymous SNPs also limits the interpretation of some of the results. Additional limitations to the study are the incompleteness of the dietary assessment with the 68-item FFQ and lack of validation of nutrient levels with blood biomarkers. Furthermore, the time frame of the study straddles the implementation of folate fortification in the United States (fully implemented in 1998), which may contribute to measurement error.

In summary, variants in four genes involved in one-carbon metabolism were associated with altered risk of postmenopausal breast cancer in our study. The increased risk associated with the *MTHFR* C677T and A1298C SNP combinations and the decreased risk for the *CBS* A360A SNP are consistent with the hypothesis that changes in the methyl donor synthesis can influence breast cancer development. Larger studies of one-carbon metabolism in which tag-SNPs are selected to comprehensively cover the genes of interest and gene/gene and gene/environment interactions can be assessed are needed.

References

- Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. *CA Cancer J Clin* 2007;57:43-66.
- Wickramasinghe SN, Fida S. Bone marrow cells from vitamin B12- and folate-deficient patients misincorporate uracil into DNA. *Blood* 1994;83:1656-61.
- Blount BC, Mack MM, Wehr CM, et al. Folate deficiency causes uracil misincorporation into human DNA and chromosome breakage: implications for cancer and neuronal damage. *Proc Natl Acad Sci U S A* 1997;94:3290-5.
- Balaghi M, Wagner C. DNA methylation in folate deficiency: use of CpG methylase. *Biochem Biophys Res Commun* 1993;193:1184-90.
- Lewis SJ, Harbord RM, Harris R, Smith GD. Meta-analyses of observational and genetic association studies of folate intakes or levels and breast cancer risk. *J Natl Cancer Inst* 2006;98:1607-22.
- Baglietto L, English DR, Gertig DM, Hopper JL, Giles GG. Does dietary folate intake modify effect of alcohol consumption on breast cancer risk? Prospective cohort study. *Br Med J* 2005;331:807-11.
- Zhang S, Hunter DJ, Hankinson SE, et al. A prospective study of folate intake and the risk of breast cancer. *J Am Med Assoc* 1999;281:1632-7.
- Rohan TE, Jain MG, Howe GR, Miller, AB. Dietary folate consumption and breast cancer risk. *J Natl Cancer Inst* 2000;92:266-9.
- Sellers TA, Kushi LH, Cerhan JR, et al. Dietary folate intake, alcohol, and risk of breast cancer in a prospective study of postmenopausal women. *Epidemiology* 2001;12:420-8.
- Zhang S, Willet WC, Selhub J, et al. Plasma folate, vitamin B₆, vitamin B₁₂, homocysteine, and risk of breast cancer. *J Natl Cancer Inst* 2003;95:373-80.
- Halsted CH, Villanueva JA, Devlin AM, Chandler CJ. Metabolic interactions of alcohol and folate. *J Nutr* 2002;132:2367-75.
- Martin YN, Olson JE, Ingle JN, et al. Methylentetrahydrofolate reductase haplotype tag single-nucleotide polymorphisms and risk of breast cancer. *Cancer Epidemiol Biomarkers Prev* 2006;15:2322-4.

13. Grieu F, Powell B, Beilby J, Iacopetta B. Methylene tetrahydrofolate reductase and thymidylate synthase polymorphisms are not associated with breast cancer risk or phenotype. *Anticancer Res* 2004;24:3215–9.
14. Justenhoven C, Hamann U, Pierl CB, et al. One-carbon metabolism and breast cancer risk: no association of MTHFR, MTR, and TYMS polymorphisms in the GENICA study from Germany. *Cancer Epidemiol Biomarkers Prev* 2005;14:3015–8.
15. Shrubsole MJ, Gao YT, Cai Q, et al. MTR and MTRR polymorphisms, dietary intake, and breast cancer risk. *Cancer Epidemiol Biomarkers Prev* 2006;15:586–8.
16. Feigelson HS, Jonas CR, Robertson AS, McCullough ML, Thun MJ, Calle EE. Alcohol, folate, methionine, and risk of incident breast cancer in the American Cancer Society Cancer Prevention Study II Nutrition Cohort. *Cancer Epidemiol Biomarkers Prev* 2003;12:161–4.
17. Calle EE, Rodriguez C, Jacobs EJ, et al. The American Cancer Society Cancer Prevention Study II Nutrition Cohort. *Cancer* 2002;94:2490–501.
18. Rothman KJ, Greenland S. *Modern Epidemiology*. Baltimore: Lippincott, Williams and Wilkins; 1998.
19. Hishida A, Matsuo K, Hamajima N, et al. Association between polymorphisms in the thymidylate synthase and serine hydroxymethyltransferase genes and susceptibility to malignant lymphoma. *Haematol* 2003;88:159–66.
20. Block G, Hartman A, Naughton D. A reduced dietary questionnaire: development and validation. *Epidemiology* 1990;1:58–64.
21. Block G, Coyle L, Smucker R, Harlan L. Health habits and history questionnaire: diet history and other risk factors. Personal computer system documentation. Bethesda (MD): National Cancer Institute Division of Cancer Prevention and Control, National Institutes of Health; 1989.
22. Willet W, Stampfer MJ. Total energy intake: implications for epidemiologic analyses. *Am J Epidemiol* 1986;124:17–27.
23. Flagg EW, Coates RJ, Calle EE, Potischman N, Thun MJ. Validation of the American Cancer Society Cancer Prevention Study II Nutrition Survey cohort food frequency questionnaire. *Epidemiology* 2000;11:462–8.
24. Macis D, Maisonneuve P, Johansson H, et al. Methylene tetrahydrofolate reductase (MTHFR) and breast cancer risk: a nested-case-control study and a pooled meta-analysis. *Breast Cancer Res Treat*. Epub 2007 Apr 24.
25. Brody LC, Conley M, Cox C, et al. A polymorphism, R653Q, in the trifunctional enzyme methylene tetrahydrofolate dehydrogenase/methylene tetrahydrofolate cyclohydrolase/formyltetrahydrofolate synthetase is a maternal genetic risk factor for neural tube defects: Report of the Birth Defects Research Group. *Am J Hum Genet* 2002;71:1207–15.
26. Pelletier JN, MacKenzie RE. Binding and interconversion of tetrahydrofolates at a single site in the bifunctional methylene tetrahydrofolate dehydrogenase/cyclohydrolase. *Biochemistry* 1995;34:12673–80.
27. Pwelek PD, MacKenzie RE. Methylene tetrahydrofolate cyclohydrolase is rate limiting for the enzymatic conversion of 10-formyltetrahydrofolate to 5,10-methylene tetrahydrofolate in bifunctional dehydrogenase-cyclohydrolase enzymes. *Biochemistry* 1998;37:1109–15.
28. Anguera MC, Field MS, Perry C, et al. Regulation of folate-mediated one-carbon metabolism by 10-formyltetrahydrofolate dehydrogenase. *J Biol Chem* 2006;281:18335–42.
29. Reuland SN, Vlasov AP, Krupenko SA. Disruption of a calmodulin central helix-like region of 10-formyltetrahydrofolate dehydrogenase impairs its dehydrogenase activity by uncoupling the functional domains. *J Biol Chem* 2003;278:22894–900.
30. Selhub J. Homocysteine metabolism. *Annu Rev Nutr* 1999;19:217–46.
31. De Stefano V, Dekou V, Nicaud V, et al. Linkage disequilibrium at the cystathionine b synthase (CBS) locus and the association between genetic variation at the CBS locus and plasma levels of homocysteine. *Ann Hum Genet* 1998;62:481–90.
32. Aras O, Hanson NQ, Yang F, Tsai MY. Influence of 699C>T and 1080C>T polymorphisms of the cystathionine b-synthase gene on plasma homocysteine levels. *Clin Genet* 2000;58:455–9.
33. Lievers KJA, Kluijtmans LAJ, Heil SG, et al. Cystathionine b-synthase polymorphisms and hyperhomocysteinemia: an association study. *Eur J Hum Genet* 2003;11:23–9.
34. Shen M, Rothman N, Berndt SI, et al. Polymorphisms in folate metabolic genes and lung cancer risk in Xuan Wei, China. *Lung Cancer* 2005;49:299–309.
35. Shi M, Caprau D, Romitti P, Christensen K, Murray JC. Genotype frequencies and linkage disequilibrium in the CEPH human diversity panel for variants in folate pathway genes MTHFR, MTHFD, MTRR, RFC1, and GCP2. *Birth Defects Res* 2003;67:545–9.
36. Goyette P, Christensen B, Rosenblatt DS, Rozen R. Severe and mild mutation in cis for the methylene tetrahydrofolate reductase (MTHFR) gene, and description of five novel mutations in MTHFR. *Am J Hum Genet* 1996;59:1268–75.
37. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylene tetrahydrofolate reductase. *Nat Genet* 1995;10:111–3.
38. Ueland PM, Hustad S, Schneede J, Refsum H, Vollset SE. Biological and clinical implications of the MTHFR C677T polymorphism. *Trends Pharmacol Sci* 2001;22:195–201.
39. Weisberg I, Tran P, Christensen B, Sibani S, Rozen R. A second genetic polymorphism in methylene tetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. *Mol Genet Metab* 1998;64:169–72.
40. van der Put NMJ, Gabreels F, Stevens EMB, et al. A second common mutation in the methylene tetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? *Am J Hum Genet* 1998;62:1044–51.
41. Chen J, Gammon MD, Chan W, et al. One-carbon metabolism, MTHFR polymorphisms and risk of breast cancer. *Cancer Res* 2005;65:1606–14.
42. Shrubsole MJ, Gao YT, Cai Q, et al. MTHFR polymorphisms, dietary folate intake, and breast cancer risk: results from the Shanghai Breast Cancer Study. *Cancer Epidemiol Biomarkers Prev* 2004;13:190–6.
43. Sharp L, Little J, Schofield AC, et al. Folate and breast cancer: the role of polymorphisms in methylene tetrahydrofolate reductase (MTHFR). *Cancer Lett* 2002;181:65–71.
44. Chou YC, Wu MH, Yu JC, et al. Genetic polymorphisms of the methylene tetrahydrofolate reductase gene, plasma folate levels, and breast cancer susceptibility: a case-control study in Taiwan. *Carcinogenesis* 2006;27:2295–300.
45. Sharp L, Little J. Polymorphisms in genes involved in folate metabolism and colorectal neoplasia: a HuGE review. *Am J Epidemiol* 2004;159:423–43.
46. Le Marchand L, Haiman CA, Wilkens LR, Kolonel LN, Henderson BE. MTHFR polymorphisms, diet, HRT, and breast cancer risk: the multiethnic cohort study. *Cancer Epidemiol Biomarkers Prev* 2004;13:2071–7.
47. Chou YC, Lee MS, Wu MH, et al. Plasma homocysteine as a metabolic risk factor for breast cancer: findings from a case-control study in Taiwan. *Breast Cancer Res Treat* 2007;101:199–205. Epub 2006 Jul 19.
48. Negri E, La Vecchia C, Franceschi S. Re: dietary folate consumption and breast cancer risk. *J Natl Cancer Inst* 2000;92:1270–1.
49. Shrubsole MJ, Jin F, Dai Q, et al. Dietary folate intake and breast cancer risk: results from the Shanghai breast cancer study. *Cancer Res* 2001;61:7136–41.
50. Lajous M, Lazano-Ponce E, Hernandez-Avila M, Willet WC, Romieu I. Folate, vitamin B₆, and vitamin B₁₂ intake and the risk of breast cancer among Mexican women. *Cancer Epidemiol Biomarkers Prev* 2006;15:443–8.
51. Giovannucci E, Rimm EB, Ascherio A, Stampfer MJ, Colditz GA, Willet WC. Alcohol, low-methionine-low-folate diets, and risk of colon cancer in men. *J Natl Cancer Inst* 1995;87:265–73.